

# TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design  
WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

[View Online](#)



---

Alley, Stephen C, Nicole M Okeley, and Peter D Senter, 'Antibody–Drug Conjugates: Targeted Drug Delivery for Cancer', *Current Opinion in Chemical Biology*, 14.4 (2010), 529–37 <<https://doi.org/10.1016/j.cbpa.2010.06.170>>

Baurin, N., F. Aboul-Ela, X. Barril, B. Davis, M. Drysdale, B. Dymock, and others, 'Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets', *Journal of Chemical Information and Modeling*, 44.6 (2004), 2157–66 <<https://doi.org/10.1021/ci049806z>>

Beck, Alain, Thierry Wurch, Christian Bailly, and Nathalie Corvaia, 'Strategies and Challenges for the next Generation of Therapeutic Antibodies', *Nature Reviews Immunology*, 10.5 (2010), 345–52 <<https://doi.org/10.1038/nri2747>>

Bissantz, Caterina, Bernd Kuhn, and Martin Stahl, 'A Medicinal Chemist's Guide to Molecular Interactions', *Journal of Medicinal Chemistry*, 53.14 (2010), 5061–84 <<https://doi.org/10.1021/jm100112j>>

Blake, J. F., 'Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate', *Medicinal Chemistry*, 1.6 (2005), 649–55 <<https://doi.org/10.2174/157340605774598081>>

Bradbury, Andrew R M, Sachdev Sidhu, Stefan Dübel, and John McCafferty, 'Beyond Natural Antibodies: The Power of in Vitro Display Technologies', *Nature Biotechnology*, 29.3 (2011), 245–54 <<https://doi.org/10.1038/nbt.1791>>

Brignier, Anne C., and Alan M. Gewirtz, 'Embryonic and Adult Stem Cell Therapy', *Journal of Allergy and Clinical Immunology*, 125.2 (2010), S336–44 <<https://doi.org/10.1016/j.jaci.2009.09.032>>

Castanotto, Daniela, and John J. Rossi, 'The Promises and Pitfalls of RNA-Interference-Based Therapeutics', *Nature*, 457.7228 (2009), 426–33 <<https://doi.org/10.1038/nature07758>>

Chandra, Nagasuma, 'Computational Systems Approach for Drug Target Discovery', *Expert Opinion on Drug Discovery*, 4.12 (2009), 1221–36 <<https://doi.org/10.1517/17460440903380422>>

Colquhoun, David, 'Binding, Gating, Affinity and Efficacy: The Interpretation of Structure-Activity Relationships for Agonists and of the Effects of Mutating Receptors', *British Journal of Pharmacology*, 125.5 (1998), 923–47 <<https://doi.org/10.1038/sj.bjp.0702164>>

Congreve, Miles, Gianni Chessari, Dominic Tisi, and Andrew J. Woodhead, 'Recent Developments in Fragment-Based Drug Discovery', *Journal of Medicinal Chemistry*, 51.13 (2008), 3661–80 <<https://doi.org/10.1021/jm8000373>>

Copeland, Robert Allen, *Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists* (Hoboken, N.J.: J. Wiley, 2005), Methods of biochemical analysis <<https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398>>

Cornish-Bowden, Athel, *Fundamentals of Enzyme Kinetics*, 3rd ed (London: Portland, 2004)

DiMasi, Joseph A, Ronald W Hansen, and Henry G Grabowski, 'The Price of Innovation: New Estimates of Drug Development Costs', *Journal of Health Economics*, 22.2 (2003), 151–85 <[https://doi.org/10.1016/S0167-6296\(02\)00126-1](https://doi.org/10.1016/S0167-6296(02)00126-1)>

Ducry, Laurent, and Bernhard Stump, 'Antibody-drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies', *Bioconjugate Chemistry*, 21.1 (2010), 5–13 <<https://doi.org/10.1021/bc9002019>>

Dunlop, John, 'High-Throughput Electrophysiology: An Emerging Paradigm for Ion-Channel Screening and Physiology', *Nature Reviews Drug Discovery*, 7.4 (2008), 358–68 <<https://doi.org/10.1038/nrd2552>>

Engel, Thomas and Gasteiger, J., *Chemoinformatics: A Textbook*, 2003

Fitt, R., and E. Nodder, 'Setting the Threshold for Industrial Application: The UK Diverges from Europe', *Journal of Intellectual Property Law & Practice*, 5.8 (2010), 560–65 <<https://doi.org/10.1093/jiplp/jpq061>>

Gasteiger, J., *Handbook of Chemoinformatics: From Data to Knowledge*, 2003 <<https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279>>

Gibb, Alasdair J., Foreman, John C., and Johansen, Torben, *Textbook of Receptor Pharmacology*, 3rd ed (Boca Raton, FL: CRC Press, 2011)

Grimm, Dirk, 'Small Silencing RNAs: State-of-the-Art', *Advanced Drug Delivery Reviews*, 61.9 (2009), 672–703 <<https://doi.org/10.1016/j.addr.2009.05.002>>

Gu, Jenny and Bourne, Philip E., *Structural Bioinformatics*, 2nd ed (Hoboken, N.J.: Wiley, 2008), Methods of biochemical analysis

Holliger, Philipp, and Peter J Hudson, 'Engineered Antibody Fragments and the Rise of Single Domains', *Nature Biotechnology*, 23.9 (2005), 1126–36 <<https://doi.org/10.1038/nbt1142>>

Hopkins, Andrew L., and Colin R. Groom, 'Opinion: The Druggable Genome', *Nature Reviews Drug Discovery*, 1.9 (2002), 727–30 <<https://doi.org/10.1038/nrd892>>

Hopkins, Andrew L., Colin R. Groom, and Alexander Alex, 'Ligand Efficiency: A Useful Metric for Lead Selection', *Drug Discovery Today*, 9.10 (2004), 430–31 <[https://doi.org/10.1016/S1359-6446\(04\)03069-7](https://doi.org/10.1016/S1359-6446(04)03069-7)>

## 'Human Embryonic Stem Cells: Derivation, Culture, and Differentiation: A Review'

Ikura, Mitsuhiko, and Masayori Inouye, 'NMR Structure of the Histidine Kinase Domain of the *E. Coli* Osmosensor EnvZ', *Nature*, 396.6706 (1998), 88–92  
[<https://doi.org/10.1038/23968>](https://doi.org/10.1038/23968)

Jarnagin, Kurt, 'Receptor Binding in Drug Discovery', in eLS

———, Receptor Binding in Drug Discovery, Encyclopedia of Life Sciences (Chichester: John Wiley & Sons, Ltd, 2001) [<https://doi.org/10.1038/npg.els.0000056>](https://doi.org/10.1038/npg.els.0000056)

Jinek, Martin, and Jennifer A. Doudna, 'A Three-Dimensional View of the Molecular Machinery of RNA Interference', *Nature*, 457.7228 (2009), 405–12  
[<https://doi.org/10.1038/nature07755>](https://doi.org/10.1038/nature07755)

Kalluri, Raghu, and Keizo Kanasaki, 'RNA Interference: Generic Block on Angiogenesis', *Nature*, 452.7187 (2008), 543–45 [<https://doi.org/10.1038/452543a>](https://doi.org/10.1038/452543a)

Kenakin, Terry P., 'Cellular Assays as Portals to Seven-Transmembrane Receptor-Based Drug Discovery', *Nature Reviews Drug Discovery*, 8.8 (2009), 617–26  
[<https://doi.org/10.1038/nrd2838>](https://doi.org/10.1038/nrd2838)

Khawaja, Xavier, John Dunlop, and Dianne Kowal, 'Scintillation Proximity Assay in Lead Discovery', *Expert Opinion on Drug Discovery*, 3.11 (2008), 1267–80  
[<https://doi.org/10.1517/17460441.3.11.1267>](https://doi.org/10.1517/17460441.3.11.1267)

Kola, Ismail, and John Landis, 'Opinion: Can the Pharmaceutical Industry Reduce Attrition Rates?', *Nature Reviews Drug Discovery*, 3.8 (2004), 711–16  
[<https://doi.org/10.1038/nrd1470>](https://doi.org/10.1038/nrd1470)

Krohn, Kenneth A., and Jeanne M. Link, 'Interpreting Enzyme and Receptor Kinetics: Keeping It Simple, but Not Too Simple', *Nuclear Medicine and Biology*, 30.8 (2003), 819–26  
[<https://doi.org/10.1016/S0969-8051\(03\)00132-X>](https://doi.org/10.1016/S0969-8051(03)00132-X)

Leach, Andrew R. and Gillet, Valerie J., *An Introduction to Chemoinformatics*, 2003

Lipinski, Christopher A., Franco Lombardo, Beryl W. Dominy, and Paul J. Feeney, 'Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings', *Advanced Drug Delivery Reviews*, 23.1–3 (1997), 3–25 [<https://doi.org/10.1016/S0169-409X\(96\)00423-1>](https://doi.org/10.1016/S0169-409X(96)00423-1)

Lledo, Pierre-Marie, Florian T. Merkle, and Arturo Alvarez-Buylla, 'Origin and Function of Olfactory Bulb Interneuron Diversity', *Trends in Neurosciences*, 31.8 (2008), 392–400  
[<https://doi.org/10.1016/j.tins.2008.05.006>](https://doi.org/10.1016/j.tins.2008.05.006)

Macarron, Ricardo, Martyn N. Banks, Dejan Bojanic, David J. Burns, Dragan A. Cirovic, Tina Garyantes, and others, 'Impact of High-Throughput Screening in Biomedical Research', *Nature Reviews Drug Discovery*, 10.3 (2011), 188–95 [<https://doi.org/10.1038/nrd3368>](https://doi.org/10.1038/nrd3368)  
Matter, Hans, 'Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors', *Journal of Medicinal Chemistry*, 40.8 (1997), 1219–29  
[<https://doi.org/10.1021/jm960352+>](https://doi.org/10.1021/jm960352+)

Murray, Christopher W., 'Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency', *Journal of Medicinal Chemistry*, 53.16 (2010), 5942–55 <<https://doi.org/10.1021/jm100059d>>

Murray, Christopher W., and David C. Rees, 'The Rise of Fragment-Based Drug Discovery', *Nature Chemistry*, 1.3 (2009), 187–92 <<https://doi.org/10.1038/nchem.217>>

Nagorsen, Dirk, and Patrick A. Baeuerle, 'Immunomodulatory Therapy of Cancer with T Cell-Engaging BiTE Antibody Blinatumomab', *Experimental Cell Research*, 317.9 (2011), 1255–60 <<https://doi.org/10.1016/j.yexcr.2011.03.010>>

Nelson, David L., Cox, Michael M., and Lehninger, Albert L., *Lehninger Principles of Biochemistry*, 5th ed (Basingstoke: W.H. Freeman, 2008)

Orengo, Christine Ann, Thornton, Janet M., and Jones, David Tudor, *Bioinformatics: Genes, Proteins and Computers* (Oxford: BIOS, 2003)  
<<http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828>>

Overington, John P., Bissan Al-Lazikani, and Andrew L. Hopkins, 'How Many Drug Targets Are There?', *Nature Reviews Drug Discovery*, 5.12 (2006), 993–96  
<<https://doi.org/10.1038/nrd2199>>

Patrick, Graham L., *An Introduction to Medicinal Chemistry*, 2017

Petsko, Gregory A. and Ringe, Dagmar, *Protein Structure and Function* (London: New Science, 2004), Primers in biology

Pillay, Vinochani, Hui K. Gan, and Andrew M. Scott, 'Antibodies in Oncology', *New Biotechnology*, 28.5 (2011), 518–29 <<https://doi.org/10.1016/j.nbt.2011.03.021>>

Rang, H. P. and Dale, M. Maureen, *Pharmacology*, 9th ed (Edinburgh: Churchill Livingstone, 2019) <<https://elsevierlibrary.co.uk/product/9780702074462>>

Richard M. Durbin, 'A Map of Human Genome Variation from Population-Scale Sequencing', *Nature*, 467.7319 (2010), 1061–73 <<https://doi.org/10.1038/nature09534>>

Schrama, David, Ralph A. Reisfeld, and Jürgen C. Becker, 'Antibody Targeted Drugs as Cancer Therapeutics', *Nature Reviews Drug Discovery*, 5.2 (2006), 147–59  
<<https://doi.org/10.1038/nrd1957>>

Selzer, P. M., Rohwer, A., and Marhöfer, R. J., *Applied Bioinformatics: An Introduction* (Berlin: Springer, 2008)

Shen, J, R Samul, R L Silva, H Akiyama, H Liu, Y Saishin, and others, 'Suppression of Ocular Neovascularization with siRNA Targeting VEGF Receptor 1', *Gene Therapy*, 13.3 (2005), 225–34 <<https://doi.org/10.1038/sj.gt.3302641>>

Smith, Roger A, 'Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach', *Bioorganic & Medicinal Chemistry Letters*, 11.20 (2001), 2775–78  
<[https://doi.org/10.1016/S0960-894X\(01\)00571-6](https://doi.org/10.1016/S0960-894X(01)00571-6)>

Stadtfeld, M., and K. Hochedlinger, 'Induced Pluripotency: History, Mechanisms, and Applications', *Genes & Development*, 24.20 (2010), 2239-63  
[<https://doi.org/10.1101/gad.1963910>](https://doi.org/10.1101/gad.1963910)

Swinney, David C., and Jason Anthony, 'How Were New Medicines Discovered?', *Nature Reviews Drug Discovery*, 10.7 (2011), 507-19 [<https://doi.org/10.1038/nrd3480>](https://doi.org/10.1038/nrd3480)

Thomas, Gareth, *Fundamentals of Medicinal Chemistry*, 2003

Vaishnav, Akshay K, Jared Gollob, Christina Gamba-Vitalo, Renta Hutabarat, Dinah Sah, Rachel Meyers, and others, 'A Status Report on RNAi Therapeutics', *Silence*, 1.1 (2010) [<https://doi.org/10.1186/1758-907X-1-14>](https://doi.org/10.1186/1758-907X-1-14)

Veber, Daniel F., Stephen R. Johnson, Hung-Yuan Cheng, Brian R. Smith, Keith W. Ward, and Kenneth D. Kopple, 'Molecular Properties That Influence the Oral Bioavailability of Drug Candidates', *Journal of Medicinal Chemistry*, 45.12 (2002), 2615-23  
[<https://doi.org/10.1021/jm020017n>](https://doi.org/10.1021/jm020017n)

Watt, F. M., and R. R. Driskell, 'The Therapeutic Potential of Stem Cells', *Philosophical Transactions of the Royal Society B: Biological Sciences*, 365.1537 (2010), 155-63  
[<https://doi.org/10.1098/rstb.2009.0149>](https://doi.org/10.1098/rstb.2009.0149)

Webb, Sarah, 'Pharma Interest Surges in Antibody Drug Conjugates', *Nature Biotechnology*, 29.4 (2011), 297-98 [<https://doi.org/10.1038/nbt0411-297>](https://doi.org/10.1038/nbt0411-297)

Weiner, Louis M., Rishi Surana, and Shangzi Wang, 'Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy', *Nature Reviews Immunology*, 10.5 (2010), 317-27  
[<https://doi.org/10.1038/nri2744>](https://doi.org/10.1038/nri2744)

Welsch, Matthew E, Scott A Snyder, and Brent R Stockwell, 'Privileged Scaffolds for Library Design and Drug Discovery', *Current Opinion in Chemical Biology*, 14.3 (2010), 347-61  
[<https://doi.org/10.1016/j.cbpa.2010.02.018>](https://doi.org/10.1016/j.cbpa.2010.02.018)

Wilhelm, Scott, 'Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer', *Nature Reviews Drug Discovery*, 5.10 (2006), 835-44  
[<https://doi.org/10.1038/nrd2130>](https://doi.org/10.1038/nrd2130)

Willett, P., J.M. Barnard, and G.M. Downs, 'Chemical Similarity Searching', *Journal of Chemical Information and Modeling*, 38.6 (1998), 983-96  
[<https://doi.org/10.1021/ci9800211>](https://doi.org/10.1021/ci9800211)

Woodhead, Andrew J., 'Discovery of (2,4-Dihydroxy-5-Isopropylphenyl)-[5-(4-Methylpiperazin-1-Ylmethyl)-1,3-Dihydroisoindol-2-Yl]Methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design', *Journal of Medicinal Chemistry*, 53.16 (2010), 5956-69  
[<https://doi.org/10.1021/jm100060b>](https://doi.org/10.1021/jm100060b)

Xiong, Jin, *Essential Bioinformatics* (New York: Cambridge University Press, 2006)

Zvelebil, Marketa J. and Baum, Jeremy O., *Understanding Bioinformatics* (London: Garland Science, 2008)  
[<https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlEx/index.html#page\\_Cove>](https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlEx/index.html#page_Cove)

r>